Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Antipsychotics
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • Parkinson Disease
  • Psychotic Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Antipsychotics can be used in the short-term to manage dementia-related psychosis, but serious adverse effects can outweigh benefits. Novel antipsychotics or other agents may offer superior efficacy and safety. Explore the evidence in this CME activity.
  • Psychopharmacology
  • Side Effects
  • Depression
  • Bipolar Disorder
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Join Dr Goldberg as he reviews factors that impact the diagnosis of bipolar disorder and current treatments for bipolar depression in adults.
  • Psychopharmacology
  • Side Effects
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are the evidence-based pharmacologic treatment approaches for pediatric patients with bipolar depression?
  • Patient/Physician Communication
  • Mood Disorders
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Antipsychotics
  • Antidepressants
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Read this rapid update in gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes.
  • Muscular Dystrophy
  • Psychopharmacology
  • Patient/Physician Communication
  • Obsessive-Compulsive and Related Disorders
  • Violence/Aggression
  • Sleep
  • Side Effects
  • Delivery of Care
  • Cognition
  • Child and Adolescent Psychiatry
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Diagnostic Tools
  • Weight
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone discuss the burden of, signs and symptoms of, diagnostic tools and criteria for mild cognitive impairment (MCI) and mild/early dementia and the benefits of early diagnosis. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression

Pages